What is the current Price Target for the Talaris Therapeutics Inc stock?

The average Talaris Therapeutics Inc target price is $57.63. This is 20.31% higher than the current stock price. The highest price target is 53.44%, the lowest is -26.20%. 12 Analysts have issued a price target Talaris Therapeutics Inc 2026 .

How high will the Talaris Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Talaris Therapeutics Inc stock will rise. The performance of stocks, including the Talaris Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Talaris Therapeutics Inc stock today?

The performance of Talaris Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Talaris Therapeutics Inc stock fall?

The decline in Talaris Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Talaris Therapeutics Inc Forecast, price target & analysts

$47.90

0.06% yesterday

Nasdaq, Oct 03, 10:00 pm CET

ISIN

US87410C1045

Symbol

TRML

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Talaris Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Talaris Therapeutics Inc Classifications & Recommendation:

Buy

40%

Hold

60%

Talaris Therapeutics Inc Price Target

Target Price	$57.63
Price	$47.90
Potential	20.31% register free of charge
Number of Estimates	12

	12 Analysts have issued a price target Talaris Therapeutics Inc 2026 . The average Talaris Therapeutics Inc target price is $57.63. This is 20.31% register free of charge higher than the current stock price. The highest price target is $73.50 53.44% register free of charge , the lowest is $35.35 26.20% register free of charge .
	A rating was issued by 15 analysts: 6 Analysts recommend Talaris Therapeutics Inc to buy, 9 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Talaris Therapeutics Inc stock has an average upside potential 2026 of 20.31% register free of charge . Most analysts recommend the Talaris Therapeutics Inc stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.89	-3.61
	67.42%	24.91%
P/E		negative
EV/Sales		129.60

12 Analysts have issued a Talaris Therapeutics Inc forecast for earnings per share. The average Talaris Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.89	67.42%
2025	$-3.61 24.91% Unlock
2026	$-4.16 15.24% Unlock
2027	$-5.29 27.16% Unlock
2028	$-5.68 7.37% Unlock
2029	$-4.94 13.03% Unlock
2030	$-1.39 71.86% Unlock
2031	$4.75 441.73% Unlock
2032	$13.08 175.37% Unlock

Current	-13.97	22.91%
2025	-13.28 4.91% Unlock
2026	-11.53 13.18% Unlock
2027	-9.05 21.51% Unlock
2028	-8.44 6.74% Unlock
2029	-9.70 14.93% Unlock
2030	-34.45 255.15% Unlock
2031	10.08 129.26% Unlock
2032	3.66 63.69% Unlock

Talaris Therapeutics Inc...

Current Talaris Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
BMO Capital	Locked ➜ Locked	Locked	Sep 15 2025
Piper Sandler	Locked ➜ Locked	Locked	Sep 11 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 10 2025
Truist Securities	Locked ➜ Locked	Locked	Sep 10 2025
Chardan Capital	Locked ➜ Locked	Locked	Sep 10 2025
Guggenheim	Locked ➜ Locked	Locked	Sep 10 2025
Jefferies	Locked ➜ Locked	Locked	Sep 09 2025

Analyst Rating	Date
Locked BMO Capital: Locked ➜ Locked	Sep 15 2025
Locked Piper Sandler: Locked ➜ Locked	Sep 11 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 10 2025
Locked Truist Securities: Locked ➜ Locked	Sep 10 2025
Locked Chardan Capital: Locked ➜ Locked	Sep 10 2025
Locked Guggenheim: Locked ➜ Locked	Sep 10 2025
Locked Jefferies: Locked ➜ Locked	Sep 09 2025

Discover more stocks with a high price target

TUI 44.74%

Novo Nordisk 34.62%

Deutsche Telekom 33.33%

BioNTech SE - ADR 32.47%

Meta Platforms (Facebook) 24.89%

Microsoft 23.72%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now